

# Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review

Christine Herbst,<sup>1</sup> Fareed A. Rehan,<sup>1</sup> Corinne Brilliant,<sup>1</sup> Julia Bohlius,<sup>2</sup> Nicole Skoetz,<sup>1</sup> Holger Schulz,<sup>1</sup> Ina Monsef,<sup>1</sup> Lena Specht,<sup>3</sup> and Andreas Engert<sup>1</sup>

<sup>1</sup>Department I of Internal Medicine, Cochrane Haematological Malignancies Group (CHMG), University Hospital Cologne, Germany; <sup>2</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, and <sup>3</sup>Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

This paper contains a Supplementary Appendix. Funding: the review was funded by the German Ministry for Education and Research (BMBF) under grant number 01KG0815. The agency had no influence on the design, conduct, analysis, writing the paper nor on the decision to submit the paper for publication.

Manuscript received August 14, 2009. Revised version arrived September 17, 2009. Manuscript accepted September 17, 2009.

Correspondence: Andreas Engert, Department I of Internal Medicine, Cochrane Haematological Malignancies Group (CHMG), University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany. E-mail: a.engert@uni-koeln.de

Citation: Herbst C, Rehan FA, Brilliant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, and Engert A. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. *Haematologica* 2009. doi:10.3324/haematol.2009.015644

©2010 Ferrata Storti Foundation. This is an open-access paper.

Online Supplementary Table 1. Characteristics of trials included only in sensitivity analyses.

Trial	Patients	Time of randomization	Treatments	Subgroup of early stage patients reported?	Median length of observation (years)	Overall survival	Tumor control
Laskar 2004	All stages, age <70 years	In CR	6 x ABVD vs. 6 x ABVD + (mainly) IF-RT	yes; stage I-II: CT: 44 CT+RT: 55	8	CT: 98% CT+RT: 100%	CT: 94% CT+RT: 97%
Nachman 2002	Children with any stage of HL	In CR	For early stages: 4x COPP/ABV vs. 4x COPP/ABV + low dose IF-RT	yes; stage I-II: CT: 173 CT+RT: 189	3	100% in both groups	CT: 91%± 2.8 (SE) CT+RT: 97% ±1.7 (SE)
O'Dwyer 1985	stages IB to IIIA	Before treatment	MOPP versus MOPP +RT	no CT: 17 CT+RT : 16	6	CT: 2 patients died CT+RT: 3 patients died	CT: 4 patients relapsed CT+RT: 3 patients relapsed
Picardi 2007	bulky HL with residual masses in CT that were PET negative at restaging after CT	In CR	6x VEBEP versus 6x VEBEP + RT	yes; CT: 52 CT+RT: 53	5	100% in both groups	# of patients who relapsed: CT: 6/52 CT+RT: 0/53
<i>Trials where the number of cycles of chemotherapy varies between trial arms.</i>							
Kung 2006	Children, PS I-IIIa	In CR or PR	6x MOPP/ABVD vs. 4x MOPP/ABVD + IF-RT	no (31% IIIA)	8	CT: 93.6%±3.9% CT+RT: 96.8%±2.7% p=0.79	CT: 82.6%±5.9% CT+RT: 91.1%± 4.5% p=0.15
Meyer 2005	Early stage (I-IIA); absence of bulky disease	Before treatment	4-6 x ABVD vs. 2 x ABVD + SN-RT	only early stage	5	HR =1.76 (0.62, 4.68)	HR=0.33 (0.14, 0.80)

NR: not reported; ABVD: adriamycin, bleomycin, vinblastine, dacarbazine; COPP: cyclophosphamide, vincristine, procarbazine and prednisolone; MOPP: mechlorethamine, vincristine, procarbazine, prednisone; VEBEP: etoposide, epirubicin, bleomycin, cyclophosphamide, prednisone; RT: radiotherapy; IF-RT: involved-field radiotherapy; SN-RT: subtotal-nodal radiotherapy; CT: chemotherapy; OS: overall survival.